Guidance for laboratories performing molecular pathology for cancer patients

Journal of Clinical Pathology

Volumn 67, Issue 11, 2014, Pages 923-931

  Cree, Ian A ^a,b   Deans, Zandra ^c   Ligtenberg, Marjolijn J L ^d   Groenen, Patricia ^d   Van Krieken, J Han ^d   Normanno, Nicola ^e   Edsjö, Anders ^f   Rouleau, Etienne ^g   Solé, Francesc ^h   Thunnissen, Erik ⁱ   Timens, Wim ^j   Schuuring, Ed ^j   Dequeker, Elisabeth ^k   Murray, Samuel ^l   Dietel, Manfred ^m  

^a UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e Cell Biology and Biotherapy Unit   (Italy)

^f SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^g Service de génétique HÔpital européen Georges Pompidou   (France)

^h JOSEP CARRERAS LEUKAEMIA RESEARCH INSTITUTE IJC   (Spain)

ⁱ VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^j UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^k UNIVERSITY OF LEUVEN   (Belgium)

^l Biomarker Solutions Ltd   (United Kingdom)

^m CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER PATIENT; CLINICAL LABORATORY; DNA EXTRACTION; HUMAN; MOLECULAR PATHOLOGY; PRACTICE GUIDELINE; QUALITY CONTROL; RNA EXTRACTION; TISSUE FIXATION; WORKFLOW; GENETIC SCREENING; GENETICS; LABORATORY; LABORATORY DIAGNOSIS; MEDICAL RECORD; NEOPLASMS; ONCOLOGY; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; STANDARDS;

TUMOR MARKER;

BENCHMARKING; GENETIC TESTING; GUIDELINE ADHERENCE; HUMANS; LABORATORIES; MEDICAL ONCOLOGY; MEDICAL RECORDS; NEOPLASMS; PATHOLOGY, MOLECULAR; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SPECIMEN HANDLING; TUMOR MARKERS, BIOLOGICAL;

EID: 84908491991     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2014-202404     Document Type: Article

References (51)

1. Dancey JE, Bedard PL, Onetto N, et al. The genetic basis for cancer treatment decisions. Cell 2012;148:409-20.
2. van Krieken JH, Normanno N, Blackhall F, et al. Guideline on the requirements of external quality assessment programs in molecular pathology. Virchows Arch 2013;462:27-37.
3. Bartlett JM, Ibrahim M, Jasani B, et al. External quality assurance of HER2 FISH and ISH testing: three years of the UK national external quality assurance scheme. Am J Clin Pathol 2009;131:106-11.
4. Perez EA, Suman VJ, Davidson NE, et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 2006;24:3032-8.
5. Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med 2013;137:828-60.
6. Sullivan W, Evans DG, Newman WG, et al. Developing national guidance on genetic testing for breast cancer predisposition: the role of economic evidence? Genet Test Mol Biomarkers 2012;16:580-91.
7. Saunders N, Zambon M, Sharp I, et al. Guidance on the development and validation of diagnostic tests that depend on nucleic acid amplification and detection. J Clin Virology 2013;56:260-70.
8. Ellis IO, Bartlett J, Dowsett M, et al. Best Practice No 176: Updated recommendations for HER2 testing in the UK. J Clin Pathol 2004;57:233-7.
9. van Krieken JH, Siebers AG, Normanno N, et al. European consensus conference for external quality assessment in molecular pathology. Ann Oncol 2013;24:1958-63.
10. Groenen PJ, Blokx WA, Diepenbroek C, et al. Preparing pathology for personalized medicine: possibilities for improvement of the pre-analytical phase. Histopathology 2011;59:1-7.
11. Di Nicolantonio F, Mercer SJ, Knight LA, et al. Cancer cell adaptation to chemotherapy. BMC Cancer 2005;5:78.
12. Crowley E, Di Nicolantonio F, Loupakis F, et al. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol 2013;10:472-84.
13. Diaz LA Jr, Williams RT, Wu J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012;486:537-40.
14. Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012;486:532-6.
15. Goldstein NS, Hewitt SM, Taylor CR, et al. Recommendations for improved standardization of immunohistochemistry. Appl Immunohistochem Mol Morphol 2007;15:124-33.
16. Hicks DG, Boyce BF. The challenge and importance of standardizing pre-analytical variables in surgical pathology specimens for clinical care and translational research. Biotech Histochem 2012;87:14-17.
17. Bai Y, Tolles J, Cheng H, et al. Quantitative assessment shows loss of antigenic epitopes as a function of pre-analytic variables. Lab Invest 2011;91:1253-61.
18. Bussolati G, Chiusa L, Cimino A, et al. Tissue transfer to pathology labs: under vacuum is the safe alternative to formalin. Virchows Arch 2008;452:229-31.
19. Bussolati G, Annaratone L, Medico E, et al. Formalin fixation at low temperature better preserves nucleic acid integrity. PloS ONE 2011;6:e21043.
20. Schuurbiers OC, Looijen-Salamon MG, Ligtenberg MJ, et al. A brief retrospective report on the feasibility of epidermal growth factor receptor and KRAS mutation analysis in transesophageal ultrasound- and endobronchial ultrasound-guided fine needle cytological aspirates. J Thorac Oncol 2010;5:1664-7.
21. Bruno P, Mariotta S, Ricci A, et al. Reliability of direct sequencing of EGFR: comparison between cytological and histological samples from the same patient. Anticancer Res 2011;31:4207-10.
22. Sun PL, Jin Y, Kim H, et al. High concordance of EGFR mutation status between histologic and corresponding cytologic specimens of lung adenocarcinomas. Cancer Cytopathol 2013;121:311-19.
23. Mitiushkina NV, Iyevleva AG, Poltoratskiy AN, et al. Detection of EGFR mutations and EML4-ALK rearrangements in lung adenocarcinomas using archived cytological slides. Cancer Cytopathol 2013;121:370-6.
24. Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 2014;6:224ra24.
25. Forshew T, Murtaza M, Parkinson C, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med 2012;4:136ra68.
26. Wickham CL, Boyce M, Joyner MV, et al. Amplification of PCR products in excess of 600 base pairs using DNA extracted from decalcified, paraffin wax embedded bone marrow trephine biopsies. Mol Pathol 2000;53:19-23.
27. de Jong D, Verbeke S, Meijer D, et al. Opening the archives for state of the art tumour genetic research: sample processing for array-CGH using decalcified, formalin-fixed, paraffin-embedded tissue-derived DNA samples. BMC Res Notes 2011;4:1.
28. Singh VM, Salunga RC, Huang VJ, et al. Analysis of the effect of various decalcification agents on the quantity and quality of nucleic acid (DNA and RNA) recovered from bone biopsies. Ann Diagn Pathol 2013;17:322-6.
29. Dietrich D, Uhl B, Sailer V, et al. Improved PCR performance using template DNA from formalin-fixed and paraffin-embedded tissues by overcoming PCR inhibition. PloS ONE 2013;8:e77771.
30. Glaysher S, Gabriel FG, Johnson P, et al. Molecular basis of chemosensitivity of platinum pre-treated ovarian cancer to chemotherapy. Br J Cancer 2010;103:656-62.
31. Dijkstra JR, Heideman DA, Meijer GA, et al. KRAS mutation analysis on low percentage of colon cancer cells: the importance of quality assurance. Virchows Arch 2013;462:39-46.
32. Mead R, Duku M, Bhandari P, et al. Circulating tumour markers can define patients with normal colons, benign polyps, and cancers. Br J Cancer 2011;105:239-45.
33. Bonin S, Hlubek F, Benhattar J, et al. Multicentre validation study of nucleic acids extraction from FFPE tissues. Virchows Arch 2010;457:309-17.
34. Normanno N, Rachiglio AM, Roma C, et al. Molecular diagnostics and personalized medicine in oncology: challenges and opportunities. J Cell Biochem 2013;114:514-24.
35. Li T, Kung HJ, Mack PC, et al. Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol 2013;31:1039-49.
36. Westgard JO, Groth T, Aronsson T, et al. Combined Shewhart-cusum control chart for improved quality control in clinical chemistry. Clin Chem 1977;23:1881-7.
37. Westgard JO, Groth T, Aronsson T, et al. Performance characteristics of rules for internal quality control: probabilities for false rejection and error detection. Clin Chem 1977;23:1857-67.
38. Cox SL, Zlot AI, Silvey K, et al. Patterns of cancer genetic testing: a randomized survey of Oregon clinicians. J Cancer Epidemiol 2012;2012:294730.
39. Tembuyser L, Ligtenberg MJ, Normanno N, et al. Higher quality of molecular testing, an unfulfilled priority: results from external quality assessment for KRAS mutation testing in colorectal cancer. J Mol Diagn 2014;16:371-7.
40. van Krieken JH, Langerak AW, Macintyre EA, et al. Improved reliability of lymphoma diagnostics via PCR-based clonality testing: report of the BIOMED-2 Concerted Action BHM4-CT98-3936. Leukemia 2007;21:201-6.
41. Baskovich BW, Allan RW. Web-based synoptic reporting for cancer checklists. J Pathol Inform 2011;2:16.
42. Gulley ML, Braziel RM, Halling KC, et al. Clinical laboratory reports in molecular pathology. Arch Pathol Lab Med 2007;131:852-63.
43. Srigley J, Lankshear S, Brierley J, et al. Closing the quality loop: facilitating improvement in oncology practice through timely access to clinical performance indicators. J Oncol Pract 2013;9:e255-61.
44. Thunnissen E, Kerr KM, Herth FJ, et al. The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group. Lung Cancer 2012;76:1-18.
45. Normanno N, Pinto C, Taddei G, et al. Results of the First Italian External Quality Assurance Scheme for somatic EGFR mutation testing in non-small-cell lung cancer. J Thorac Oncol 2013;8:773-8.
46. Normanno N, Pinto C, Castiglione F, et al. KRAS mutations testing in colorectal carcinoma patients in Italy: from guidelines to external quality assessment. PloS ONE 2011;6:e29146.
47. Berwouts S, Morris MA, Dequeker E. Approaches to quality management and accreditation in a genetic testing laboratory. Eur J Hum Genet 2010;18(Suppl 1):S1-19.
48. Bellon E, Ligtenberg MJ, Tejpar S, et al. External quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds. Oncologist 2011;16:467-78.
49. Dubbink HJ, Deans ZC, Tops BB, et al. Next generation diagnostic molecular pathology: Critical appraisal of quality assurance in Europe. Mol Oncol 2014;8:830-9.
50. Dijkstra JR, Opdam FJ, Boonyaratanakornkit J, et al. Implementation of formalin-fixed, paraffin-embedded cell line pellets as high-quality process controls in quality assessment programs for KRAS mutation analysis. J Mol Diagn 2012;14:187-91.
51. Taylor S, Bennett KM, Deignan JL, et al. Molecular pathology curriculum for medical laboratory scientists: a report of the association for molecular pathology training and education committee. J Mol Diagn 2014;16:288-96.